Murielle Mauer

European Organisation for Research and Treatment of Cancer — Netherlands

Medicine · Health Sciences

38h-index9.5kcitations135works4.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(45), Gastric Cancer Management and Outcomes(29), Hepatocellular Carcinoma Treatment and Prognosis(20), Health Systems, Economic Evaluations, Quality of Life(15), Colorectal Cancer Surgical Treatments(14)

Publications135 total

Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis
European Journal of Cancer·2025
QOL-22. Prognostic associations of the G8 geriatric screening tool in the EORTC Brain Tumor Group trials 1608 and 1709 in newly diagnosed glioblastoma
Neuro-Oncology·2025Open Access
Diagnostic Accuracy of Imaging in Assessing Nonviability of Disappearing Colorectal Liver Metastasis
JAMA Surgery·2025· 6 citedOpen Access
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)
ESMO Open·2025· 3 citedOpen Access
2889 PRIMALung (EORTC-1901) preliminary data: PRophylactic cerebral Irradiation (PCI) or active brain MRI surveillance in SCLC patients
Radiotherapy and Oncology·2025
EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases
Cancer Treatment Reviews·2025· 10 citedOpen Access
EORTC-1203 GITC "INNOVATION": Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: Overall survival results.
Journal of Clinical Oncology·2025· 8 cited
EORTC1527/JCOG1609INT/ESSO02: Diffusion-weighted magnetic resonance imaging (DW-MRI) assessment of initially unresectable liver metastasis to improve surgical planning (DREAM)—Primary analysis.
Journal of Clinical Oncology·2025
PRIMALung (EORTC-1901): PRophylactic cerebral irradiation (PCI) or active brain MAgnetic resonance imaging (MRI) surveillance in small-cell lung cancer (SCLC) patients
Lung Cancer·2024· 10 citedOpen Access
Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction
JAMA Network Open·2024· 9 citedOpen Access
EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol
ESMO Gastrointestinal Oncology·2024· 2 citedOpen Access
EORTC 1409 GITCG/ESSO 01 - A prospective colorectal liver metastasis database for borderline or initially unresectable diseases (CLIMB): Lessons learnt from real life. From paradigm to unmet need
European Journal of Surgical Oncology·2023· 5 citedOpen Access
Assessing patient-reported outcomes (PROs) and patient-related outcomes in randomized cancer clinical trials for older adults: Results of DATECAN-ELDERLY initiative
Journal of Geriatric Oncology·2023· 17 citedOpen Access
Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma
Journal of Clinical Oncology·2023· 31 citedOpen Access
O-5 Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) - subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG
Annals of Oncology·2023· 6 citedOpen Access
Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group.
Journal of Clinical Oncology·2023· 25 cited
Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase II study.
Journal of Clinical Oncology·2023· 5 cited
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial
Lung Cancer·2022· 2 citedOpen Access
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
The Lancet Oncology·2022· 698 cited
EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.
Journal of Clinical Oncology·2022· 20 cited
page 1 of 7Next →

Frequent Co-authors

Bernard Nordlinger(16), Eric Van Cutsem(14), Manfred P. Lutz(14), Wolf O. Bechstein(10), Florian Lordick(10), Michel Ducreux(8), Dorothea Wagner(8), Markus Moehler(8), Corneel Coens(7), Andrew Bottomley(7), Graeme J. Poston(6), Laurence Collette(6), Frits van Coevorden(6), Jonathan A. Ledermann(6), Karin Haustermans(6), Halfdan Sørbye(5), Thomas Gruenberger(5), Sandrine Marréaud(5), M.A. Lentz(5), Arnaud Roth(5)